Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Sint-Niklaas – page 7

121 clinical trials in Sint-Niklaas, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sint-Niklaas at a glance
121
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

121 trials in Sint-Niklaas

Open in trial search

Head and neck cancer metastatic

Not recruiting

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not recruiting

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
  • Sponsor:Novartis Pharma AG

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Major depression

Not recruiting

Study on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Pleural mesothelioma malignant

Not recruiting

Study of WT1 LAMP mRNA DC Vaccine for Patients with Malignant Pleural Mesothelioma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:WT1 LAMP mRNA DC
  • Sponsor:Antwerp University Hospital

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Lung neoplasm malignant

Not recruiting

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Squamous cell carcinoma of head and neck

Not recruiting

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Sint-Niklaas

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on lung cancer treatments, including both small cell and non-small cell variants. Multiple trials evaluating novel combination therapies with chemotherapy and immunotherapy agents.

  • Lung Cancer Therapeutics
  • Breast Cancer Treatment
  • Head and Neck Cancer

Studies include evaluation of targeted therapies for specific cancer mutations and biomarkers.

02 Gastroenterology Studies

Clinical investigations focusing on inflammatory bowel conditions, including Crohn's disease and ulcerative colitis. Trials evaluating new therapeutic approaches for disease management.

  • Inflammatory Bowel Disease
  • Hepatitis Treatment
  • Disease Activity Assessment

Research emphasizes both therapeutic intervention and disease monitoring strategies.

03 Cardiovascular Research

Studies examining treatments for coronary artery disease and stroke prevention in patients with atrial fibrillation. Trials evaluating novel anticoagulation approaches.

  • Stroke Prevention
  • Post-PCI Treatment
  • Cardiac Therapeutics

Focus on both preventive measures and post-intervention care strategies.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.